Drug firm Laurus Labs on Thursday said it has received an establishment inspection report from the US health regulator for two of its active pharmaceutical ingredients units at Visakhapatnam in Andhra Pradesh.
The establishment inspection report (EIR) from US Food and Drug Administration (USFDA) is for company's active pharmaceutical ingredients units 1 and 3, at Visakhapatnam, for the inspection conducted in June 2019, Laurus Labs said in a filing to BSE.
The company has also received approval from the Global Fund (GF) expert review panel for its fixed dose combination, TLE 400, for supply in GF-funded projects, it added.
Laurus Labs is one among the three companies to receive the approval for this product in antiretroviral therapy, the company said.
TLE 400 is the alternative first line regimen for treatment of HIV/AIDS as per the World Health Organization guidelines issued in July 2019, it added.
Shares of Laurus Labs were trading at Rs 330.95 per scrip on BSE, up 1.36 per cent from its previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app